TY  - JOUR
AU  - Reissig, T. M.
AU  - Tzianopoulos, I.
AU  - Liffers, S-T
AU  - Rosery, Vivian Katrin
AU  - Guyot, M.
AU  - Ting, S.
AU  - Wiesweg, M.
AU  - Kasper, S.
AU  - Meister, P.
AU  - Herold, T.
AU  - Schmidt, H. H.
AU  - Schumacher, B.
AU  - Albers, D.
AU  - Markus, P.
AU  - Treckmann, J.
AU  - Schuler, M.
AU  - Schildhaus, H-U
AU  - Siveke, J. T.
TI  - Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
JO  - ESMO open
VL  - 8
IS  - 3
SN  - 2059-7029
CY  - London
PB  - BMJ
M1  - DKFZ-2023-00917
SP  - 101539
PY  - 2023
AB  - Pancreatic cancer has a dismal prognosis. One reason is resistance to cytotoxic drugs. Molecularly matched therapies might overcome this resistance but the best approach to identify those patients who may benefit is unknown. Therefore, we sought to evaluate a molecularly guided treatment approach.We retrospectively analyzed the clinical outcome and mutational status of patients with pancreatic cancer who received molecular profiling at the West German Cancer Center Essen from 2016 to 2021. We carried out a 47-gene DNA next-generation sequencing (NGS) panel. Furthermore, we assessed microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status and, sequentially and only in case of KRAS wild-type, gene fusions via RNA-based NGS. Patient data and treatment were retrieved from the electronic medical records.Of 190 included patients, 171 had pancreatic ductal adenocarcinoma (90
KW  - Archer (Other)
KW  - KRAS wild-type (Other)
KW  - NGS (Other)
KW  - targeted sequencing (Other)
KW  - targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37148593
DO  - DOI:10.1016/j.esmoop.2023.101539
UR  - https://inrepo02.dkfz.de/record/275929
ER  -